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Molecular Targeted Agents and Biologic Therapies for
Non-small Cell Lung Cancer
Neeta Somaiah, MD,* and George R. Simon, MD, FACP, FCCP†
Tabulated below are “targeted” or novel agents that arebeing or have been evaluated in non-small cell lung
cancer (NSCLC) and small cell lung cancer. Only compounds
that have entered clinical trials have been listed. The com-
pounds are listed by class, and under each class, they are
listed in the order of their phase of clinical development, with
those in the latest phase being listed first. The phase of
development in lung cancer is also noted if it differs from the
latest phase of development in other malignancies. The
classes are listed alphabetically, except for the first two
categories (epidermal growth factor receptor and vascular
endothelial growth factor receptor inhibitors) because drugs
from this category are approved for NSCLC and are in
common clinical practice. Drugs that do not fall into specific
broad categories are clumped under “others” at the end of the
Table 1. We have made every attempt to be current and
comprehensive, and this table is essentially designed to be
a quick reference tool; however, the information listed is
dynamic and constantly evolving, and therefore, the reader
is encouraged to look for further updates that may have
been reported after the publication of this table. This is
especially pertinent for compounds currently undergoing phase
III testing.
In the last column, the list of toxicities is given. This list
is not intended to be comprehensive, but only the prototypic
or most commonly seen “class effect” toxicities are noted.
The toxicity column has been left blank for compounds very
early in development for which mature toxicity data are not
available. The phase of the trial is also listed in the last but
one column. If the phase of development in lung cancer
differs from the overall development of the agent, then this
has been explicitly stated. Compounds still in phase I devel-
opment has been also listed. Nevertheless, only those com-
pounds of potential utility for lung cancer and that are also
enrolling patients with lung cancer are listed. If a compound
is undergoing lung cancer-specific phase I testing, then this
has also been stated.
When available, the generic name, trade name(s),
and other accepted name(s) or phrase(s) used to refer an
agent have also been listed. A blank space indicates that a
generic or trade name did not exist at the time of writing.
Nevertheless, this might have changed by the time this
article is published.
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TABLE 1. Summary of Novel Agents Being Tested in Lung Cancer
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Epidermal growth factor
receptor (EGFR)
inhibitors
ImClone/Eli Lilly Bristol-
Myers Squibb
Cetuximab Erbitux IMC-C225
Genentech/OSI
Pharmaceuticals
Erlotinib Tarceva OSI-774
AstraZeneca Gefitinib Iressa ZD 1839
GlaxoSmithKline Lapatinib Tykerb GW 572016
Amgen Panitumumab Vectibix ABX-EGF MAb
Boehringer Ingelheim Tovok BIBW-2992
Pfizer PF299804
Wyeth Neratinib HKI-272
Bristol-Myers Squibb BMS-690514/EVR1
Pfizer Canertinib CI-1033
Wyeth Pelitinib EKB-569
Merck Serono/Takeda Matuzumab EMD 72000
YM BioSciences Nimotuzumab h-R3
Genmab Zalutumumab HuMax-EGFr
Roche RO5083945/GA201
Betapharma Icotinib BPI-2009H
Bristol-Myers
Squibb/Ambit
Biosciences
BMS-599626
AVEO pharmaceuticals AV-412
Vascular endothelial growth
factor (VEGF) and VEGF
receptor (VEGFR)
inhibitors
Genentech Bevacizumab Avastin
Bayer Sorafenib Nexavar BAY43–9006
Pfizer Sunitinib Sutent SU 011248
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TABLE 1. (Continued)
Type Targets
Current Phase of
Development
Significant
Side Effects
Chimeric MoAb EGFR FDA approved -head and neck cancer -
colorectal cancer Ph III studies for
NSCLC have been completed and
reported. Recommended by NCCN for
first-line use with cisplatin and
vinorelbine in patients with advanced
NSCLC who are IHC positive for EGFR
Rash and other skin toxicities, nail
changes, diarrhea, infusion
reaction, headache,
hypomagnesemia
Reversible small molecule TKI EGFR FDA approved-metastatic NSCLC after
failure of at least one prior regimen -
Maintenance therapy in patients in
advanced NSCLC having stable disease
or better as best response after first-line
chemotherapy -in combination with
Gemcitabine for advanced pancreatic
cancer
Skin toxicity, diarrhea
Reversible small molecule TKI EGFR FDA approved for NSCLCa Skin toxicity, diarrhea, interstitial
lung disease
Reversible small molecule TKI EGFR, HER2 (erb-B2) FDA approved for HER2-overexpressing
breast cancer
Diarrhea, nausea, vomiting,
dermatologic (palmar-plantar
erythrodysesthesia and rash),
fatigue, hepatotoxicity,
Human IgG2 MoAb EGFR FDA approved for colorectal cancer Hypomagnesemia, paronychia,
fatigue, nausea, diarrhea,
infusion reaction
Ph II for NSCLC
Irreversible small molecule TKI EGFR, HER2 Ph III Rash, acne, diarrhea
Irreversible small molecule TKI Pan-HER Ph III Diarrhea, acne, rash
Irreversible small molecule TKI EGFR, HER2 Ph II Diarrhea, asthenia, rash
Small molecule TKI EGFR, HER2, VEGFR2 Ph I/II Diarrhea, rash, hypertension,
pulmonary embolism,
neutropenia, reversible posterior
leukoencephalopathy
Irreversible small molecule TKI Pan- HER Ph II No longer in clinical development in
NSCLC
Rash, diarrhea, asthenia, stomatitis
Irreversible small molecule TKI EGFR, HER2, HER4 Ph II Diarrhea, rash, nausea, asthenia
Humanized MoAb EGFR Ph II Rash, diarrhea
Humanized MoAb EGFR Ph I/II Rash, diarrhea
Human MoAb EGFR Ph III No longer in clinical development
for lung
Rash, fatigue, pyrexia
Glyco-engineered anti-EGFR IgG1
MoAb
EGFR (also improved antibody
dependent cellular
cytotoxicity
Ph I Infusion reactions
Small molecule TKI EGFR Ph I/IIa (China)
Reversible small molecule inhibitor EGFR, HER2, HER4 Ph I
Irreversible small molecule TKI EGFR/HER2 Ph I (study terminated)
Humanized MoAb VEGF-A FDA approved -metastatic HER2 negative
breast -metastatic colorectal -metastatic
NSCLC -Phase III testing on going in the
adjuvant setting (ECOG 1505)
Hypertension, proteinuria,
thrombosis, hemorrhage,
gastrointestinal perforation
Small molecule TKI VEGFR-2, 3, PDGFR , KIT,
RAF/MEK, FLT-3
FDA approved -unresectable hepatocellular
cancer -advanced renal cell carcinoma Ph
III for NSCLC
Rash/desquamation, hand-foot skin
reaction, diarrhea, fatigue,
hypertension
Small molecule TKI VEGFR-1, 2, 3, PDGFR ,
KIT, FLT-3, RET
FDA approved -gastrointestinal stromal
tumor -advanced renal cell carcinoma Ph
III for NSCLC
Hypertension, rash, stomatitis,
diarrhea, hypothyroidism, hand-
foot syndrome
(Continued)
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TABLE 1. (Continued)
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
GlaxoSmithKline Pazopanib Votrient GW786034
Sanofi-Aventis Aflibercept TBA VEGF-TRAP AVE0005
AstraZeneca Cediranib Recentin AZD2171
Amgen/Takeda Motesanib AMG706
Aeterna Zentaris Neovastat AE941
Boehringer Ingelheim Vargatef BIBF 1120
AstraZeneca Vandetanib Zactima ZD6474
Exelixis XL647
Adnexus (Bristol-Myers
Squibb)
Adnectin CT-322
Pfizer Axitinib AG013736
ImClone/Eli Lilly Ramucirumab IMC-1121B
Novartis/Bayer Schering Vatalanib PTK787/ZK 222584
AVEO Pharmaceuticals Tivozanib AV-951
Abbott Linifanib ABT-869
Exelixis XL184
Exelixis XL999
Bayor Regorafenib BAY73–4506
Eisai Limited E7080
GlaxoSmithKline Foretinib GSK1363089/XL880
Novartis AEE 788
Exelixis XL820
Anaplastic lymphoma kinase
(ALK) inhibitor
Pfizer Crizotinib PF-02341066
BCL-2 inhibitors Abbott & Genentech ABT-263/ABT-737
GeminX Obatoclax GX15–070
Ascenta Gossypol AT101
Genasense Oblimerson G3139
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TABLE 1. (Continued)
Type Targets
Current Phase of
Development
Significant
Side Effects
Small molecule TKI VEGFR-1, 2, 3, PDGFR , ,
KIT
FDA approved for advanced renal cell
carcinoma Ph II/III for NSCLC
Nausea, hypertension, diarrhea,
fatigue, anorexia, vomiting, hair
depigmentation.
Fusion protein of extracellular
domain portions from VEGFR-1
and VEGFR-2 combined with Fc
of human IgG
VEGF, placental growth factor
(PIGF)
Ph III Hypertension, abdominal pain,
anorexia, diarrhea, fatigue
Small molecule TKI VEGFR-1, 2, 3, PDGFR , KIT Ph III Diarrhea, dysphonia, hypertension
Small molecule TKI VEGFR-1, 2, 3, PDGFR ,
KIT, RET
Ph III Nausea, diarrhea, fatigue,
hypertension
Natural product from shark
cartilage
VEGFR-2, MMP-2, 9, 12 Ph III completed No longer in clinical
development for lung cancer
Taste alteration
Small molecule TKI VEGFR-1, 2, 3, PDGFR-, ,
FGFR-1, 2, 3, Src kinases
Ph III Nausea, vomiting, elevated liver
enzymes, diarrhea
Small molecule TKI VEGFR-2, 3, EGFR, RET Ph III Hypertension, diarrhea, rash
Irreversible small molecule TKI VEGFR-2, EGFR, HER2,
EphB4
Ph I/II Diarrhea, rash, fatigue, nausea,
hypertension, anorexia
Fibronectin-based small protein VEGFR-2 Ph II Proteinuria, hypertension
Small molecule TKI VEGFR-1, 2, 3, PDGFR , KIT Ph II Diarrhea, hypertension, fatigue,
nausea, hand-foot syndrome,
proteinuria
Human MoAb VEGFR-2 Ph II Hypertension, abdominal pain,
nausea, anorexia, headache,
proteinuria, deep venous
thrombosis (DVT).
Small molecule TKI VEGFR-1, 2, PDGFR , KIT Ph I/II Hypertension, diarrhea, nausea,
fatigue, dizziness
Small molecule inhibitor Pan VEGFR-1, 2, 3 Ph I/II Nausea, vomiting, diarrhea,
hoarseness, myalgias,
hypertension
Small molecule TKI VEGFR, PDGFR Ph II Fatigue, hypertension, proteinuria,
hand foot skin reaction
Small molecule TKI VEGFR-2, MET, RET Ph I/II Diarrhea, mucositis, anorexia,
vomiting, hand-foot skin
reaction, hypertension, elevation
of liver enzymes
Small molecule TKI VEGFR, PDGFR, FLT-3, Src,
FGFR
Ph II Elevation of liver enzymes
Diphenylurea multikinase inhibitor VEGFR-1, 2, 3, TIE2,
PDGFR, FGFR, KIT, RET,
RAF
Ph II Ph I for NSCLC Hand-foot skin reaction, extremity
pain, hypothyroidism, rash
Small molecule TKI VEGFR-2 (also 1, 3), FGFR-2,
RET
Ph I Hypertension, fatigue, proteinuria,
anorexia, diarrhea, dysphonia
Small molecule TKI VEGFR-2, MET Ph II
Irreversible small molecule TKI VEGFR-2, EGFR, HER2 Ph I/II
Small molecule TKI VEGFR-2, PDGFR , KIT Ph II No active lung trials
Dual small molecule ATP
competitive inhibitor
Anaplastic lymphoma kinase
(ALK)/c-Met
Ph III in NSCLC patients with Echinoderm
microtubule-associated protein-like 4
(EML4)-ALK fusion gene
Nausea, diarrhea, visual disturbances,
alanine aminotransferase elevation,
fatigue
Small molecule inhibitor (ABT-263
is orally bioavailable)
Bad-like BH3 mimetic Ph II for small cell lung cancer (SCLC) Diarrhea, back pain,
thrombocytopenia
Small molecule inhibitor Pan Bcl-2 Ph II for SCLC Neurotoxicity, cytopenias
Small molecule inhibitor Pan Bcl-2 Ph II for SCLC Gastrointestinal side effects
Antisense oligodeoxyribonucleotide Bcl-2 Ph II Ph I for lung cancer Fever, elevated liver enzymes
(Continued)
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TABLE 1. (Continued)
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Src/BCR-ABL tyrosine kinase
inhibitors (TKIs)
Bristol-Myers Squibb Dasatinib Sprycel BMS-354825
Novartis Imatinib Gleevec STI-571
AstraZeneca AZD 0530
Kinex Pharmaceuticals KX2–391
Epigenetic modulators of gene
expression or protein
degradation
Heat shock protein (HSP)-
90 inhibitors
Infinity Retaspimycin IPI-504
Synta Pharmaceuticals STA-9090
Novartis AUY922
Kosan Biosciences Tanespimycin KOS-953
Kosan Biosciences Alvespimycin KOS-1022
Histone deacetylase
(HDAC) inhibitors
Merck Vorinostat Zolinza MK 0683/SAHA
Syndax Pharmaceuticals Entinostat MS-275
CuraGen Belinostat PXD 101
Gloucester Pharmaceuticals Romidepsin FR901228
Titan Pivanex (pivaloyloxymethyl
butyrate)
AN-9
Valproic acid Depakote
Sodium phenylbutyrate
Novartis Panobinostat Faridak LBH589
Chroma Therapeutics CHR-3996
Curis CUDC-101
SaBIO SB939
Proteasome inhibitors Millennium
Pharmaceuticals
Bortezomib Velcade PS-341
Onyx Pharmaceuticals Carfilzomib PR-171
Nereus Pharmaceuticals Salinosporamide A NPI-0052
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TABLE 1. (Continued)
Type Targets
Current Phase of
Development
Significant
Side Effects
Small molecule TKI of SRC-family Src, BCR-ABL, KIT, PDGFR,
FMS or colony stimulating
factor 1 receptor CSF1R
FDA approved for chronic myelogenous
leukemia Ph II for NSCLC
Fatigue, pleural effusion, diarrhea,
myelosuppression, rash
Small molecule TKI KIT, PDGFR, BCR-ABL fusion
protein
FDA approved for gastrointestinal stromal
tumor, dermatofibrosarcoma protuberans
-Philadelphia chromosome positive
chronic myelogenous leukemia Ph II for
NSCLC
Fluid retention, diarrhea,
myelosuppression, rash
Small molecule TKI of SRC-family
binds the active conformation of
the ATP binding pocket
Src, BCR-ABL Ph II Leukopenia, febrile neutropenia,
asthenia
Small molecule TKI targeting the
substrate binding site
c-Src Ph I Hypokalemia, anemia, elevated
AST, fatigue, dyspnea, fever,
vomiting, constipation,
hematuria, lymphopenia
Water-soluble geldanamycin
derivative
HSP-90 Ph III, Ph II for NSCLC Fatigue, nausea, diarrhea, renal
failure, liver failure
Small molecule inhibitor HSP-90 Ph II Diarrhea, anemia, fatigue,
abdominal pain, elevated alkaline
phosphatase, constipation
Isoxazole-based compound
(nongeldanamycin)
HSP90 Ph I Diarrhea, nausea, fatigue, visual
symptoms, vomiting
Benzoquinone antineoplastic
antibiotic
HSP-90 Ph I Fatigue, lymphopenia
Benzoquinone antineoplastic
antibiotic
HSP-90 Ph I
Small molecule inhibitor
(hydroxamic acid type)
Class I, II, and IV FDA approved for 3rd line cutaneous T-cell
Lymphoma, Ph III (lung)
Diarrhea, nausea, fatigue,
thrombocytopenia, muscle
spasms
Small molecule inhibitor
(benzamide derivative)
Class I specific Ph II Pancytopenia, hypophosphatemia,
nausea, fatigue
Small molecule inhibitor
(hydroxamic acid type)
Class I and II isoforms Ph II Nausea, emesis, fatigue
Cyclic tetrapeptide (antibiotic from
chromobacterium violaceum)
Class I specific Ph II Fatigue, thrombocytopenia, nausea
Small molecule inhibitor (short
chain fatty acid)
Class I and IIa specific Ph II Fatigue, nausea, dysgeusia
Small molecule inhibitor (short
chain fatty acid)
Class I and IIa specific Ph I Anemia, neurologic toxicity,
nausea, hepatic toxicity
Small molecule inhibitor (short
chain fatty acid)
Class I and IIa specific Ph I Neurocortical toxicity,
hypokalemia, hyponatremia,
hyperuricemia, nausea
Small molecule inhibitor
(hydroxamic acid type)
Pan-HDAC (all isoforms) Ph I QT interval prolongation, nausea,
diarrhea, hypokalemia,
thrombocytopenia
Small molecule inhibitor Class I HDAC isoforms Ph I Fatigue, nausea, vomiting
Small molecule inhibitor HDAC, HER2, EGFR Ph I
Small molecule HDAC inhibitor HDAC Ph II, Ph I for lung (no ongoing trials) Fatigue, troponin elevation, QTc
prolongation
Reversible inhibitor 26S proteasome and client
proteins (i.e., p27, p53,
NFkB, Bcl-2, and Bax)
FDA approved for -multiple myeloma-
mantle cell lymphoma, Ph II for NSCLC
Asthenia, nausea, diarrhea,
constipation, peripheral
neuropathy, hypotension,
thrombocytopenia
Irreversible inhibitor 20S proteasome subunit Ph II Pancytopenia, peripheral
neuropathy
Irreversible inhibitor 20S catalytic core subunit of the
proteasome
Ph I Fatigue, nausea, neurologic toxicity
(Continued)
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TABLE 1. (Continued)
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Millennium
Pharmaceuticals
MLN9708
Cephalon and Ethical
Oncology Science
CEP-18770
Fibroblast growth factor
receptor (FGFR)
inhibitors
Novartis TKI-258
Bristol-Myers Squibb Brivanib Alaninate BMS-582664
Taiho Pharmaceutical TSU-68
Eisai E-7080
Five Prime therapeutics FP-1039
Hedgehog antagonists Genentech GDC-0449
Novartis LDE 225
Infinity IPI-926
Bristol-Myers Squibb BMS-33923/XL-1395
Hormone therapy AstraZeneca Fulvestrant Faslodex ICI 182780
AstraZeneca Anastrazole Arimidex
Human epidermal growth
factor receptor 2 (HER2)
inhibitors
Genentech Trastuzumab Herceptin
Genentech/Roche Pertuzumab
Hypoxia-activated prodrug Threshold Pharmaceuticals TH-302
Proacta PR-104
Novacea AQ4N
SRI International Tirapazamine SR-4233
Hypoxia inducible factor-1
(HIF-1) inhibitor
Oncothyreon PX-478
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TABLE 1. (Continued)
Type Targets
Current Phase of
Development
Significant
Side Effects
Reversible inhibitor 20S proteasome subunit Ph I
Slowly reversible Inhibits chymotrypsin-like
activity of proteasome
Ph I
Small molecule inhibitor FGFR-1, 2, 3, PDGFR,
VEGFR-2
Ph II Hypertension, anorexia, nausea,
vomiting, fatigue, headache
Small molecule TKI FGFR and VEGFR-2 Ph II Hypertension, fatigue
Small molecule inhibitor FGFR, PDGFR, VEGFR Ph I/II Fatigue, AST/ALT elevation,
diarrhea
Small molecule inhibitor FGFR, PDGFR, VEGFR Ph I Hypertension, proteinuria,
neutropenia
Soluble fusion protein consisting of
a portion of the FGFR1
FGF ligand trap (multiple FGFs) Ph I
Small molecule inhibitor Smoothened receptor in the
hedgehog pathway
Ph II for small cell lung cancer Dysguesia, hyponatremia, fatigue
Small molecule inhibitor Smoothened receptor in the
hedgehog pathway
Ph I Fatigue, nausea, vomiting,
anorexia, muscle cramps,
dysgeusia
Small molecule inhibitor Smoothened receptor in the
hedgehog pathway
Ph I
Small molecule inhibitor Smoothened receptor in the
hedgehog pathway
Ph I
Blocks estrogen activity through
receptor
Estrogen Receptor (ER) FDA approved for hormone receptor
positive breast cancer, Ph II (lung)
Hot flashes, injection site reaction,
headache, gastrointestinal
disturbances, back pain
Decreases estrogen in
postmenopausal women
Aromatase inhibitor Ph II Hot flashes, joint disorders,
osteoporosis, nausea, mood
changes, hypertension
Humanized MoAb Her2 FDA approved for HER2-overexpressing
breast cancer, Ph II for NSCLC
Cardiomyopathy, infusion
reactions, diarrhea
Humanized murine MoAb Prevents dimerization of HER2
with other HER receptors
Ph III, Ph II for NSCLC Fatigue, diarrhea
Tumor selective hypoxia activated
prodrug
2-nitroimidazole moiety is
triggered by hypoxic
conditions to release DNA-
alkylating dibromo
isophosphoramide mustard
Ph I Cytopenias, fatigue, nausea,
mucositis
Tumor selective hypoxia activated
pre-prodrug
Converted to a prodrug which is
reduced under hypoxic
conditions to a hydroxylamine
metabolite, PR-104H, which
is a cytotoxic nitrogen
mustard alkylating agent.
Ph I Cytopenias, nausea, vomiting,
fatigue
Tumor selective hypoxia activated
prodrug
Converted selectively under
hypoxic conditions to the
drug’s active form, AQ4, a
potent topoisomerase II
inhibitor
Ph I
Benzotriazine di-N-oxide which
acts as a hypoxia activated
cytotoxin
Forms free radicals in hypoxic
cells that cause DNA damage.
Also sensitizes hypoxic cells
to ionizing radiation and
inhibits the repair via
inhibition of topoisomerase II
Ph III small cell lung cancer., No longer
underdevelopment for lung cancer
Ototoxicity, muscle cramps, nausea,
vomiting
Small molecule inhibitor HIF-1 Ph I
(Continued)
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TABLE 1. (Continued)
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Immunomodulatory agents Celgene Lenalidomide Revlimid CC-5013
Celgene Thalidomide Thalomid
Agennix Talactoferrin rhLF
Bristol-Myers Squibb Ipilimumab MDX 010
Bristol-Myers Squibb BMS-663513
Inhibitor of apoptosis proteins
(IAPs)
Human Genome Sciences/
Aegera
HGS 1029/AEG 40826
Insulin growth factor-1
receptor (IGF-1R)
inhibitor
Pfizer Figitumumab CP-751871
ImClone Cixutumumab IMC-A12
Merck MK-0646
Amgen AMG 479
Biogen Idec BIIB022
OSI Pharmaceuticals OSI906
Bristol-Myers Squibb BMS-754807
Immunogen/Sanofi-Aventis AVE1642
Genmab & Roche R1507
Integrins Merck Serono Cilengitide EMD121974
PDL BioPharma & Biogen
Idec
Volociximab M200
Mammalian target of
rapamycin (mTOR)
inhibitors
Wyeth Temsirolimus Torisel CCI-779
Novartis Everolimus Afinitor RAD001
Merck/Ariad Ridaforolimus AP-23573
Sirolimus Rapamune Rapamycin
OSI Pharmaceuticals OSI 027
AstraZeneca AZD 8055
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TABLE 1. (Continued)
Type Targets
Current Phase of
Development
Significant
Side Effects
Immunomodulatory,
antiinflammatory,
antiangiogenic
FDA approved for -multiple myeloma, -
myelodysplastic syndrome, Ph II for
NSCLC
Myelosuppression, rash, thrombosis
Immunomodulatory,
antiinflammatory,
antiangiogenic
FDA approved for -multiple myeloma, Ph
II for NSCLC
Somnolence, peripheral neuropathy,
dizziness, neutropenia,
thrombosis, rash
Recombinant human lactoferrin Dendritic cell recruiter and
activator
Ph III Diarrhea
IgG1 Human MoAb Cytotoxic T-lymphocyte
antigen-4 (CTLA-4)
Ph II for lung cancer. Phase III studies
completed for Melanoma
Rash, diarrhea (autoimmune
colitis),
hypothyroidism,hypophisitis,
hepatitis
Humanized MoAb Agonist of CD-137, a TNF
receptor
Ph II (Terminated) Phase I in combination
with chemotherapy and radiation therapy
in NSCLC (terminated)
Neutropenia, elevated liver
enzymes, rash, pruritis, diarrhea
Pan-IAP inhibitor Ph I Nausea, anorexia, diarrhea, fatigue,
elevated amylase and lipase,
supraventricular tachycardia
IgG2 type human MoAb IGF-1R Ph II completed, Ph III terminated Hyperglycemia, asthenia, anorexia,
pneumonia, dehydration, early
death.
IgG1 type human MoAb IGF-1R Ph II Pruritis, rash, anemia,
hyperglycemia, infusion-related
reaction
IgG1 type humanized MoAb IGF-1R Ph II Fatigue, hyperglycemia, nausea,
constipation, diarrhea
IgG1 type human MoAb IGF-1R Ph I/II Thrombocytopenia, hyperglycemia,
fatigue, rash, elevated LFTs,
asymptomatic TSH increase
Human nonglycosylated IgG4
MoAb
IGF-1R Ph II, Ph I for NSCLC Hypertension, fatigue, dyspnea,
QTc prolongation
Small molecule inhibitor IGF-1R and insulin receptor
(IR)
Ph I Nausea, vomiting, fatigue,
hyperglycemia, elevated liver
enzymes
Small molecule reversible inhibitor IGF-1R and IR Ph I Fatigue, hyperglycemia
Humanized MoAb IGF-1R Ph I, (No active trials) Hyperglycemia, asthenia,
hypersensitivity
IgG1 type human MoAb IGF-1R Ph II (Development is halted) Fatigue, anorexia, weight loss
Cyclic peptide  v  3 and  v  5 integrin Ph II Lymphopenia, thrombocytopenia,
neutropenia, fatigue, nausea,
anorexia
Chimeric MoAb  5  1 integrin Ph II, Ph Ib (lung) Fatigue, nausea, constipation,
diarrhea, arthralgia
Ester analog of rapamycin mTORC1 FDA approved -advanced renal cell
carcinoma, Ph II for NSCLC
Fatigue, rash, asthenia,
hyperglycemia, hyperlipemia,
hypophosphatemia,
myelosuppression, nausea,
diarrhea
Derivative of the natural
macrocyclic lactone sirolimus
mTORC1 FDA approved -advanced renal cell
carcinoma, Ph II for NSCLC
Stomatitis, asthenia, pneumonitis,
fatigue, infections, diarrhea,
neutropenia
Small molecule serine/threonine
kinase inhibitor
mTOR Ph II Fatigue, anorexia, mucositis
A macrolide derived from
Streptomyces hygroscopicus
mTORC1 Ph I/II Cytopenias, hypoalbuminemia,
hyperglycemia,
hypercholesterolemia,
hypertriglyceridemia
Small molecule inhibitor mTORC1, 2 Ph I
ATP competitive small molecule
inhibitor
mTOR C1, 2 Ph I
(Continued)
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TABLE 1. (Continued)
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Matrix metalloproteinase
inhibitors
Shionogi S-3304
c-MET/hepatocyte growth
factor receptor (HGFR)
pathway inhibitors
ArQule ARQ197
Amgen AMG 102
Amgen AMG 208
Schering-Plough/AVEO SCH900105
Pfizer PF-04217903
SGX Pharmaceuticals SGX523
Mitogen-activated protein/
extracellular signal-
regulated kinase (MEK)
inhibitors
AstraZeneca/Array
BioPharma
AZD6244
Pfizer PD325901
AstraZeneca/Array
BioPharma
AZD8330
GlaxoSmithKline GSK1120212
Ardea Biosciences RDEA119
Genentech GDC-0973/XL518
Merck Serono AS 703026
Inhibitors of mitosis
Aurora kinase inhibitors Merck MK5108
AstraZeneca AZD 1152
Millennium
Pharmaceuticals
MLN 8237
Merck Tozasertib MK0457
Checkpoint kinase (Chk)
inhibitor
AstraZeneca AZD7762
Kinesin protein inhibitors GlaxoSmithKline Ispinesib SB-715992
GlaxoSmithKline SB-743921
GlaxoSmithKline GSK-923295
Array BioPharma ARRY-520
Merck MK0731
AstraZeneca AZD4877
ArQule ARQ-621
Eli Lilly/Kyowa Hakko
Kirin
LY-2523355
Polo-like kinase inhibitor Boehringer Ingelheim BI-2536
Boehringer Ingelheim BI-6727
Notch pathway inhibitors Roche RO 4929097
Pfizer PF03084014
Merck MK0752
Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 6, December 2010 Santa Monica Supplement
Copyright © 2010 by the International Association for the Study of Lung Cancer S445
TABLE 1. (Continued)
Type Targets
Current Phase of
Development
Significant
Side Effects
Noncytotoxic inhibitor of MMPs MMP-2 MMP-9 Ph I/II Gastrointestinal toxicities, including
dairrhea
Small molecule inhibitor c-Met/HGFR Ph II Hepatotoxicity
Human IgG2 MoAb HGF (ligand) Ph Ib/II Fatigue, constipation, anorexia,
nausea, dyspnea
Small molecule inhibitor c-Met Ph I
Humanized IgG1 MoAb HGF (ligand) Ph I Fatigue, edema, headache, diarrhea
Small molecule inhibitor c-Met/HGFR Ph I
Selective small molecule inhibitor Met Ph I (Discontinued) Nephrotoxicity, fatigue, pyrexia,
nausea, vomiting
ATP uncompetitive inhibitor MEK 1 Ph II Rash, diarrhea, nausea, emesis
Small molecule inhibitor MEK Ph II (Terminated) Ocular toxicity, neurologic toxicity
Small molecule inhibitor MEK 1 Ph I
Allosteric inhibitor MEK 1/2 Ph I Rash, diarrhea, central retinopathy
Allosteric inhibitor MEK 1/2 Ph I
Small molecule inhibitor MEK 1 Ph I
Noncompetitive small molecule
inhibitor
MEK 1/2 Ph I Asthenia, diarrhea, constipation,
rash, nausea, vomiting
Small molecule inhibitor Aurora A kinase Ph I Not significant (cytopenias with
chemotherapy)
Aurora B kinase Ph I Neutropenia
Small molecule serine/threonine
protein kinase inhibitor
Aurora kinase A Ph I Somnolence, nausea, neutropenia,
fatigue
Small molecule serine/threonine
protein kinase inhibitor
Aurora kinase family Ph II (halted due to cardiac risk) Neutropenia, nausea, mucositis
ATP-competitive inhibitor of Chk,
potentiating DNA targeting
therapies
Chk1/2 Ph I
Small molecule Mitotic kinesin spindle protein/
kinesin 5 (KSP)
Ph II Neutropenia, fatigue, anemia,
elevated creatinine, lymphopenia,
hyperglycemia (no neuropathy-
like Taxanes)
Small molecule KSP Ph I Neutropenia, hypophosphatemia,
transaminitis
Small molecule Centromere-linked kinesin-like
motor protein CENP-E
(kinesin 7)
Ph I
Small molecule KSP Ph I (more activity in hematologic
malignancies)
Cytopenias, nausea, vomiting,
fatigue, hyponatremia
Small molecule KSP Ph I Neutropenia, diarrhea, nausea,
mucositis, anorexia
KSP Ph II , No active trials in lung Neutropenia
Small molecule KSP Ph I
KSP Ph II
ATP competitive small molecule
inhibitor
Plk1 (serine threonine kinase) Ph II Neutropenia, fatigue, nausea
Ph II
Small molecule inhibitor  secretase inhibitor (key
enzyme in the Notch
pathway)
Ph I/II Fatigue, nausea, diarrhea,
hypophosphatemia, rash.
Small molecule inhibitor  secretase inhibitor (has effects
on Notch, Jagged 1, CD44,
E-cadherin and N-cadherin
Ph I Gastrointestinal toxicity (reduced
with steroids)
Small molecule inhibitor Notch Ph I Abdominal pain, diarrhea, nausea,
fatigue
(Continued)
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TABLE 1. (Continued)
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Osteoclast function modifiers
(important in bone
metastasis)
Novartis Zoledronate Zometa
Amgen Denosumab AMG-162
Etidronate Didronel
Novartis Alendronate Fosamax
AstraZeneca AZD0530
Merck L-000845704
PI3K/mTOR/AKT/MEK
inhibitors
Akt inhibitors Agouron Pharmaceuticals Nelfinavir Viracept AG 1343
Keryx Perifosine KRX-0401
Phosphatidylinositol-3-
kinase (PI-3K) inhibitors
Novartis BEZ235
Novartis BGT226
ProlX Pharmaceuticals PX-866
Genentech GDC-0941
Exelixis XL147
Exelixis XL765
Poly(ADP-RIBOSE)
polymerase (PARP)
inhibitors
BiPar Sciences (Sanofi-
Aventis)
Iniparib BSI-201
Pfizer AG014699
Abbott Veliparib ABT 888
AstraZeneca Olaparib AZD2281
Merck MK4827
Survivin inhibitors Isis Pharmaceuticals & Eli
Lilly
LY2181308
Astellas YM155
Telomerase inhibitors Geron Corporation Imetelstat GRN163L
Sodium metaarsenite KML001
TNF-related apoptosis
inducing ligand (TRAIL)
receptor agonists
Genentech Apomab PRO95780
Human Genome Sciences Mapatumumab HGS-ETR1
Human Genome Sciences Lexatumumab HGS-ETR2
Amgen Conatumumab AMG-655
Amgen/Genentech rhApo2L/TRAIL
Novartis LBY135
Genentech/Amgen Dulanermin
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TABLE 1. (Continued)
Type Targets
Current Phase of
Development
Significant
Side Effects
Farnesyl pyrophosphate Osteoclast inhibitor FDA approved for osteoporosis and skeletal
metastases
Hypocalcemia, osteonecrosis of jaw
Fully human monoclonal antibody RANK ligand inhibitor
(transmembrane protein
important for osteoclast
activity and survival)
FDA approved for osteoporosis, Ph III for
bone metastasis
Hypocalcemia, osteonecrosis of
jaw, serious infections, skin
reactions
Bisphosphonate-ATP requiring
small molecule
Osteoclast inhibitor FDA approved for symptomatic Paget’s
disease, Ph III for bone metastasis
Esophagitis, arthralgias,
hypersensitivity reactions
Nitrogen containing bisphosphonate
targets farnesyl pyrophosphate
synthase
Osteoclast inhibitor FDA approved for osteoporosis, Ph III for
bone metastasis
Esophagitis, osteonecrosis of jaw,
delayed healing, hypersensitivity
reaction, bone/muscle pains
Inhibits Src kinase mediated
osteoclast resorption
Dual specific inhibitor of Src
and Abl
Ph II for NSCLC
Integrin antagonist- decreases bone
resorption
3 Ph III for osteoporosis., No currently
ongoing trials for Lung Cancer
Protease inhibitor Akt Ph II Diarrhea, rash, fatigue, leukopenia
Akt Ph II Nausea, vomiting, diarrhea, fatigue
Small molecule inhibitor PI-3K (p110 subunit), mTOR
complexes 1/2
Ph I/II, Preclinical (lung) Nausea, emesis, diarrhea
Small molecule inhibitor PI-3K Ph I/II
Wortmanin analog PI-3K, lowers p-mTOR, p-S6
ribosomal protein
Ph I
Pan inhibitor of class 1 PI-3K PI-3K Ph I Nausea, fatigue, diarrhea,
dysgeusia, headache, pleural
effusion
PI-3K Ph I
Small molecule inhibitor PI3K Ph I Nausea, diarrhea, transaminitis,
rash, anorexia, fatigue
Small molecule inhibitor PARP-1 Ph III (squamous)
Small molecule inhibitor PARP-1 Ph II, Ph I for NSCLC Fatigue, thrombocytopenia,
hypophosphate, infection,
lymphopenia
Small molecule inhibitor PARP-1, 2 Ph II, Ph I for lung
Small molecule inhibitor PARP Ph I
Small molecule inhibitor PARP Ph I
Antisense oligonucleotide Blocks survivin Ph I/II PTT prolongation, fever, fatigue,
nausea
Small molecule inhibitor Suppresses survivin Ph II Hypertension, neutropenia, fatigue,
nausea, stomatitis, fever.
Competitive telomerase RNA
template antagonist
Telomerase Ph I/II PTT prolongation, gastrointestinal
side effects, fatigue, anemia,
GGT elevation, peripheral
neuropathy
Oral arsenic agent Telomerase Ph I
Human IgG1 MoAb TNF related apoptosis inducing
ligand receptor 2 (TRAIL-
R2)/Death receptor 5 (DR5)
Ph II Neutropenia, elevated liver
enzymes, supraventricular
tachycardia, pulmonary
embolism
Human MoAb TRAIL-R1/DR4 Ph II Fatigue, nausea, hypotension,
transaminitis.
Human MoAb TRAIL-R2/DR5 Ph I/II Fatigue, transaminitis.
Human MoAb TRAIL-R2/DR5 Ph I/II Fever, fatigue, gastrointestinal
toxicity
Recombinant human MoAb DR4 and DR5 Ph I/II Arthralgia, myalgias, nausea,
transaminitis
Humanized MoAb TRAIL-R2/DR5 Ph I
Recombinant human protein DR4 and DR5 Ph I
(Continued)
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TABLE 1. (Continued)
Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Vascular disrupting agents
(VDA)
Antisoma & Novartis Vadimezan ASA404
Oxigene Fosbretabulin Zybrestat Combretastatin-A4
phosphate/CA4P
Nereus Pharmaceuticals Plinabulin NPI-2358
OXiGENE Combretastatin A1 diphosphate OXi4503
MediciNova MN-029
MolMed NGR-hTNF
AstraZeneca ZD6126
Vaccines NovaRx Belagenpumatucel-L Lucanix
EMD Sereno BLP25 Liposome vaccine Stimuvax
GlaxoSmithKline GSK1572932A/MAGE-A3
Bioven Sdn. Bhd (bioven) Recombinant human (rEGF)-
rP64K/
Montanide ISA 51
Transgene TG 4010 (MVA-MUC1-IL2)
University of Kentucky 1650-G Vaccine
Cell Genesys CG8123 (GVAX)
GlaxoSmithKline Astuprotimut-R GSK 249553
Antigenics Oncophage Vitespen HSPPC-96
NewLink Genetics HyperAcute-Lung Cancer
vaccine
AVAX Technologies L-Vax
NCI/RTOG/SWOG Monoclonal antibody 11D10
antiidiotype vaccine
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Type Targets
Current Phase of
Development
Significant
Side Effects
Small molecule VDA Induces tumor necrosis alpha
(TNF-alpha), serotonin and
nitric oxide
Ph III Cardiac events
Small molecule VDA Binds to tubulin dimers and
prevents microtubule
polymerization in endothelial
cells and disrupts endothelial
cell junctional molecule
vascular endothelial cadherin
Ph II Hypertension, reversible cardiac
ischemia, pulmonary embolism
Small molecule VDA Disrupts the endothelial tubulin
cytoskeleton
Ph II Nausea, vomiting, diarrhea, fatigue,
fever, tumor pain
Small molecule VDA Ph I/II Hypertension, tumor pain, fatigue,
cytopenias, nausea
Small molecule VDA Disrupts the endothelial tubulin
cytoskeleton
Ph I Nausea, vomiting, fatigue, diarrhea
CNGRC peptide-TNF  conjugate,
(NGR-hTNF is a first-in-class
compound based on the
combination of a tumour homing
peptide (NGR) with the human
Tumour Necrosis Factor (hTNF)
Membrane-bound
metalloprotease CD13
expressed on endothelial cells
Ph III Mesothelioma,, Phase II SCLC,
Phase II NSCLC
Infusion related Chills
Small molecule VDA Disrupts the endothelial tubulin
cytoskeleton
Ph I Abdominal pain, nausea, vomiting,
cardiac
Transforming growth factor beta2
(TGF-beta2) antisense gene-
modified allogeneic whole tumor
cell vaccine
Cytotoxic T lymphocyte (CTL)
response against NSCLC cells
Ph III Mild reactions -local (pain, redness,
swelling) -systemic (fever,
fatigue, muscle pain)
Synthetic peptide derived from the
mucin 1 (MUC-1) antigen
Cytotoxic T lymphocyte (CTL)
response against MUC-1-
expressing tumor cells
Ph III
Antigen-Specific Cancer
Immunotherapeutic
Cytotoxic T lymphocyte (CTL)
response against MAGE-A3
positive tumors
Ph III Mild reactions -local (pain, redness,
swelling) -systemic (fever,
fatigue, muscle pain)
rEGF linked to the Neisseria
meningitidis-derived recombinant
immunogenic carrier protein P64k
(rP64K) and mixed with
immunoadjuvant Montanide ISA 51
Antibody-mediated inhibition of
endogenous EGF binding to
its receptor, epithelial growth
factor receptor (EGFR
Ph II/III
Modified vaccinia Ankara virus
vector with Muc1 and IL-2
sequences
Cytotoxic T lymphocyte (CTL)
response against Muc1
Ph III
Allogenic cellular vaccine CTL response against NSCLC
cells
Ph II
GM-CSF gene-modified autologous
whole tumor vaccine
Cytotoxic T lymphocyte (CTL)
response against tumor cells
Ph I/II
Antigen-Specific Cancer
Immunotherapeutic
MAGE-3 positive tumors Ph III MAGRIT Mild Grade 1 or 2 local or
systemic reactions
Autologous tumor vaccine made by
extractingheat shock protein gp96
and its associated peptides
Autologous tumor cells Ph II
Alpha-1,3-galactosyltransferase-
expressing allogeneic lung tumor
cell vaccine
Complement-mediated
cytotoxicity (CMC) and
antibody-dependent cell-
mediated cytotoxicity
(ADCC) towards lung tumor
cells
Ph II
DNP (dinitrophenyl)-modified
autologous NSCLC vaccine
CTL response against NSCLC
cells
Ph I/II (Study has been suspended)
MoAb against an idiotype that
mimics a human milk fat globule
(HMFG) membrane epitope
Cells expressing HMFG
membrane epitope
Ph II (NSCLC) (Limited-Stage SCLC)
(Continued)
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Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Titan Pharmaceuticals CeaVac Monoclonal
antibody 3H1
antiidiotype vaccine
Epimmune Multiepitope cancer vaccine
( EP- 2101)
NCI Mutant p53 peptide pulsed
dendritic cell
NCI Recombinant fowlpox or
vaccinia-CEA(6D)/TRICOM
NCI CCL21
Providence Health Services DRibble vaccine
University of Miami,
Sylvester Cancer Center
Heat shock protein Gp96–1g
fusion protein expressing
vaccine
NCI MAGE-12 peptide vaccine
emulsified in Montanide
ISA-51
Corixa Corporation pVAX/L523S and Ad/L523S
NCI Ras peptide cancer vaccine
University of Pittsburgh with DNA Semiallogeneic human
fibroblasts (MRC-5)
transfected
Memorial Sloan Kettering
Cancer Center
WT-1 (Wilm’s tumor) analog
peptide vaccine
Others Telik Canfosfamide hydrochloride Telcyta TLK286
Novelos Therapeutics NOV-002
NCI Isotretinoin Several brand names
includingAccutane
Roaccutane
Multiple sponsors Bexarotene Targretin
Eli Lilly Isis
Pharmaceuticals
LY900003 Affinitac ISIS 3521
OncGenex OGX 011
Isis Pharmaceuticals ISIS 2503
Antisense Pharma Trabedersen AP 12009
Isis Pharmaceuticals ISIS 5132
Peregrine Pharmaceuticals Bavituximab Tarvacin UNII-Q16CT95N25 3G4
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Side Effects
Recombinant MoAb that mimics a
specific epitope of the
carcinoembryonic antigen (CEA)
Tumors that express CEA Ph II
DNA vaccine, emulsified in
montanide ISA-51
Tumors expressing CEA, HER2/
neu, p53, and MAGE 2/3
Ph II
Autologous dendritic cells pulsed
with a mutant p53 peptide
Tumor cells expressing mutant
p53
Ph II
Recombinant fowlpox/vaccinia
virus vector encoding
carcinoembryonic antigen (CEA)
and a TRIad of COstimulatory
Molecules (B7–1, ICAM-1 and
LFA-3) (TRICOM)
CEA-expressing tumors Ph I/II
Adenovirus CCL21 gene modified
autologous dendritic cells
Ph I
Autologous tumor vaccine Autologous tumor cells Ph I
Irradiated non-small cell lung
cancer cells, manipulated to
express and secrete heat shock
protein gp96-Ig fusion protein
CTL response against NSCLC
cells
Ph I
Peptide vaccine MAGE-12 Antigen positive
tumors
Ph I (all solid tumors)
Recombinant DNA and Adenovirus
Expressing L523S Protein
Ph I
Mutated K-Ras Ph I
Fibroblasts Transfected With DNA
From Autologous Tumor
Autologous Tumor Cells Ph I
Peptide vaccine Wilm’s tumor gene expressing
tumors
Ph I
Alkylating agent novel glutathione analog into an
alkylating metabolite by
glutathione S-transferase P1–1
(overexpressed in many
tumors)
Ph III Nausea, Vomiting, Fatigue,
Microscopic Hematuria, Anemia
Redox modulating agent Glutathione disulfide-mimetic Ph III completed Did not add to the toxicity profile
of chemotherapy when added to
chemotherapy
Retinoid Exact mechanism of action
unknown. Isotretinoin may
down-regulate the telomerase
enzyme, inhibiting cellular
immortalization and
tumorigenesis
Ph III Dryness of the skin, Acne flare and
skin rash, Raised liver enzyme,
Hyperlipedemia, Birth defects
Retinoid that selectively activates
retinoid X receptors (RXRs)
RXR, RXR, RXR Ph III Hypothyroidism, headache,
asthenia, rash, leukopenia,
nausea, peripheral edema,
abdominal pain
Antisense oligonucleotide Protein Kinase C alpha Ph III completed.
Further development discontinued
Antisense oligonucleotide Clusterin Ph II
Antisense oligonucleotide H-ras Ph II
Antisense oligonucleotide TGF-2 Ph I/II Transient thrombocytopenia
Antisense oligonucleotide Raf-1 Ph I Fever
Chimeric IgG1 MoAb Membrane phosphatidylserine
complexed with 2-
glycoprotein I on tumor
vasculature
Ph II Fever, diarrhea, alopecia, anemia,
neuropathy
(Continued)
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Class of Agent(s)
Trial Sponsoring
Entity(ies) Generic Name Trade Name Other Name(s)
Simcere pharmaceuticals Endostar Endostatin
Eli Lilly Enzastaurin LY-317615
Alder Pharmaceuticals ALD518
Acceleron and Celgene ACE-011
Merck MK-1775
Chroma Therapeutics Tosedostat CHR-2797
Pfizer PF-3512676
Pfizer PF-00562271
AstraZeneca ZD4054
Trion Pharma Catumaxomab Removab
Micromet AG MT110
Imclone LLC Ramucirumab IMC-3G3
AstraZeneca AZD 6918
Pfizer CVX-045
Eisai Inc. Eribulin mesylate E7389
Vion Pharmaceuticals, NCI Triapine
Bristol-Meyers Squibb Epofolate BMS-753493
Bristol-Meyers Squibb MDX- 1106
Daiichi Sankyo, Co., Ltd. CS 7017/RS5444
Pfizer Celecoxib Celebrex or Celebra for
arthritis; Onsenal for
polyps
Quintessence Biosciences QBI-139
Pfizer CVX-060
NCI 4-(N-(S-
glutathionylacetylamino)
phenylarsonous acid
(GSAO)
Introgen Therapeutics DOTAP: chol-FUS1
¹¹1-L19SIP
Lpath/Merck-Sereno Sonepcizumab/ASONEP
aLimited indication: only for patients with cancer who, in the opinion of their treating physician, are currently benefiting, or have previously benefited, from gefitinib treatment.
MoAb, monoclonal antibody; NSCLC, non-small cell lung cancer, TKI, tyrosine kinase inhibitor; NCI, National Cancer Institute (USA); Ph, phase.
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Recombinant human endostatin Angiogenesis inhibitors Ph III Pneumonia, pulmonary embolism
Serine threonine kinase inhibitor Protein kinase C beta Ph III, (phase II in NSCLC), Hypertension, fatigue, ataxia,
thromboembolism
Anti-IL-6 antibody To treat anemia, cachexia and
fatigue
Ph II
Fully human, soluble fusion protein
derived from the extracellular
domain of Activin Receptor Type
IIA (ActRIIA) that binds Activin
and the Fc domain of IgG1
antibody.
Increases hemoglobin and also
increases bone mineral
density
Ph II Headache, paresthesia, dizziness,
fatigue, hypertension
Sensitizes p53 negative cells to
DNA damage by abrogation of
G2 checkpoint
WEE1 inhibitor Ph I/II
Small molecule aminopeptidase
inhibitor
M1 family of aminopeptidases Ph I/II
Synthetic agonist of Toll-like
receptor 9 (TLR9)
TLR9 Ph III terminated due to lack of efficacy Sepsis
Reversible focal adhesion kinase
(FAK) inhibitor
FAK Ph I Headache, nausea, peripheral
neuropathy, diarrhea, fatigue, edema
Endothelin A Receptor (ETAR)
antagonist
ETAR Ph II
Rat-murine hybrid monoclonal
antibody binding to EpCAM and
CD3 antibody
EpCAM/CD3 Ph III (phas I/II for lung cancer), -
Approved in Europe for malignant ascitis
Fever, Nausea, Vomiting
EpCAM/CD3 bispecific antibody
construct (BiTE)
EpCAM/CD3 Ph I Fever, elevated liver enzymes
Recombinant human IgG1 MoAb PDGFR Ph II
Small molecule inhibitor Tropomyosin-related kinases (Trk) Ph I (Development discontinued)
Human MoAb Thrombospondin-1 Mimetic Ph I Fatigue, gastrointestinal upset, dyspnea,
headache, dizziness, anemia
Non-taxane microtubule dynamics
inhibitor
Ph II Fatigue, cytopenias
Ribonucleotide reductase inhibitor
(enhancing the activity of
gemcitabine)
Ph II
Folate conjugate of epothilone
analog BMS-748265
Ph I Fatigue, nausea, elevated liver
enzymes, diarrhea
Human IgG4 MoAb Programmed death-1 (PD1)
inhibitor
Ph I Nausea, fatigue, diarrhea,
xerostomia, pruritis
PPAR agonistPfozer Peroxisome proliferator receptor
(PPAR)- 
Ph II Fluid retention
Eicosanoid Cyclooxygenase-2 inhibitor Ph II
Variant of human pancreatic
ribonuclease 1
Causes destruction of RNA Ph I
Antiangiogenic COVX-Body A Selective Angiopoietin-2
(ANG-2) Binding
Ph I Fatigue, proteinuria
Synthetic tripeptide trivalent
arsenical
Angiogenesis inhibitor that
targets the mitcohondria o
actively dividing but not
quiescent endothelial cells
arresting their proliferation
and causing apoptosis
Ph I
Lipid-based nanoparticles Fus1 tumor suppressor gene Ph I Fever, hypophosphatemia
Radioimmunotherapy Selectively binds extra domain
B of fibronectin a marker of
angiogenesis
Ph I Cytopenias
Humanized MoAb Shingosine-1-phosphate Ph I Infusion reaction
Santa Monica Supplement Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 6, December 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS454
